Heart failure & cardiomyopathies
Racial Differences in Quality of Life in Patients With Heart Failure Treated With Sodium–Glucose Cotransporter 2 Inhibitors: A Patient-Level Meta-Analysis of the CHIEF-HF, DEFINE-HF, and PRESERVED-HF Trials
Authors' conclusion
Treatment with an SGLT2i resulted in consistent and significant improvements in health status for both Black and White patients with heart failure.
Study context
- Population
- Self-identified Black and White patients with HF in 3 US-based trials236 (25%) Black
- Participants
- 935 participants
- Comparison
- SGLT2 inhibitors vs placebo, Black vs White patients
- SGLT2in = 469
- Outcome
- Change in KCCQ Clinical Summary score
- Follow-up
- 12 weeks
Methodological detailsCHIEF-HF, DEFINE-HF, PRESERVED-HF, subgroup analysis by race, interaction test
- CHIEF-HF, DEFINE-HF, PRESERVED-HF
- Subgroup analysis by race
- Interaction test
Pooled result
As reported in the abstract
KCCQ Clinical Summary score change, by race
Difference
+4.0 points
95% CI 1.7–6.3P = 0.0007
White patients
Difference
+4.7 points
95% CI 0.7–8.7P = 0.02
Black patients
Further pooled results
Other Kansas City Cardiomyopathy Questionnaire (KCCQ) scales
- Similar results
Original publication
Racial Differences in Quality of Life in Patients With Heart Failure Treated With Sodium–Glucose Cotransporter 2 Inhibitors: A Patient-Level Meta-Analysis of the CHIEF-HF, DEFINE-HF, and PRESERVED-HF Trials. Circulation. Published 16 May 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →